{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    39,
    41,
    42,
    43,
    44,
    45,
    46,
    47,
    48,
    49
  ],
  "modelUsed": "gemini-3-flash-preview",
  "interventions": {
    "studyInterventions": [
      {
        "id": "int_1",
        "name": "Faricimab (RO6867461)",
        "type": {
          "id": "41e3ab51-9ffa-4f03-821f-fe30b4e30465",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "role": {
          "id": "36daaf7f-f421-4721-b6f6-e0a9f3b43ef0",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Bispecific antibody targeting Ang-2 and VEGF for the treatment of macular edema secondary to BRVO.",
        "productIds": [
          "prod_1"
        ],
        "administrationIds": [
          "admin_1"
        ]
      },
      {
        "id": "int_2",
        "name": "Aflibercept",
        "type": {
          "id": "67afaa30-7e00-412b-a0c4-af1f5fa21dd4",
          "code": "C54129",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Comparator",
          "instanceType": "Code"
        },
        "role": {
          "id": "a9e9d992-6c5f-4fea-87ff-78e7bc16f4e6",
          "code": "C54129",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Comparator",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Active comparator (anti-VEGF monotherapy) for Part 1 of the study.",
        "productIds": [
          "prod_2"
        ],
        "administrationIds": [
          "admin_2"
        ]
      },
      {
        "id": "int_3",
        "name": "Sham procedure",
        "type": {
          "id": "227498b7-b2e3-491e-8f63-2650bcdbb440",
          "code": "C41132",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Placebo",
          "instanceType": "Code"
        },
        "role": {
          "id": "7886a3d2-c526-4cd0-81f3-e2a0204adab0",
          "code": "C41132",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Placebo",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Procedure mimicking an IVT injection using the blunt end of an empty syringe to maintain masking during Part 2.",
        "administrationIds": [
          "admin_3"
        ]
      },
      {
        "id": "int_4",
        "name": "Systemic corticosteroids",
        "type": {
          "id": "32bafb0d-5c71-465e-9a9b-7fcebc978d07",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "f26be9c3-bdbd-4f8a-90a6-aec96c4df896",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Prohibited within 1 month of screening and during the study."
      },
      {
        "id": "int_5",
        "name": "Anti-VEGF IVT",
        "type": {
          "id": "32e30882-9d3e-4c83-9349-c45e9b31875c",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "75d2fff9-6899-4b04-b77a-834abaafea0a",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Prior treatment for macular edema due to RVO is a reason for exclusion (washout/prior medication)."
      },
      {
        "id": "int_6",
        "name": "Prophylactic antibiotic therapy",
        "type": {
          "id": "77f82dc7-b02e-4f2a-b6ce-0ad709c333f7",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "3f73e89b-b067-44af-b7fd-7808a8647835",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Permitted if approved by the Medical Monitor."
      }
    ],
    "administrableProducts": [
      {
        "id": "prod_1",
        "name": "Faricimab",
        "administrableDoseForm": {
          "id": "6df10e35-31cf-4223-9bc2-857113298d93",
          "code": "C42945",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Injection",
          "standardCode": {
            "id": "aaac7efe-9324-4cbc-bb8e-4b66f088ba20",
            "code": "C42945",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Injection",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "5c85c608-d3c7-4802-ae57-5418d2f79dfd",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "strength": "6 mg",
        "substanceIds": [
          "sub_1"
        ],
        "manufacturer": "F. Hoffmann-La Roche Ltd"
      },
      {
        "id": "prod_2",
        "name": "Aflibercept",
        "administrableDoseForm": {
          "id": "56e61cdb-8088-4ec1-ad47-d338295bf7b4",
          "code": "C42945",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Injection",
          "standardCode": {
            "id": "0e26d565-0df2-4f93-b73b-9a234db8b763",
            "code": "C42945",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Injection",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "af2cf728-5f44-4425-aa6e-24e0531df7bf",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "strength": "2 mg",
        "substanceIds": [
          "sub_2"
        ],
        "manufacturer": "Not specified"
      }
    ],
    "administrations": [
      {
        "id": "admin_1",
        "name": "Faricimab Part 1",
        "instanceType": "Administration",
        "dose": "6 mg",
        "doseFrequency": "every 4 weeks",
        "route": {
          "code": "Other",
          "codeSystem": "USDM",
          "decode": "Other"
        },
        "duration": "Day 1 through Week 20 (6 injections)"
      },
      {
        "id": "admin_2",
        "name": "Aflibercept Part 1",
        "instanceType": "Administration",
        "dose": "2 mg",
        "doseFrequency": "every 4 weeks",
        "route": {
          "code": "Other",
          "codeSystem": "USDM",
          "decode": "Other"
        },
        "duration": "Day 1 through Week 20 (6 injections)"
      },
      {
        "id": "admin_3",
        "name": "Faricimab Part 2 (PTI)",
        "instanceType": "Administration",
        "dose": "6 mg",
        "doseFrequency": "every 4 weeks to every 16 weeks",
        "route": {
          "code": "Other",
          "codeSystem": "USDM",
          "decode": "Other"
        },
        "duration": "Week 24 through Week 68"
      }
    ],
    "substances": [
      {
        "id": "sub_1",
        "name": "Faricimab",
        "instanceType": "Substance",
        "description": "Bispecific antibody (RO6867461)"
      },
      {
        "id": "sub_2",
        "name": "Aflibercept",
        "instanceType": "Substance",
        "description": "VEGF trap protein"
      }
    ],
    "medicalDevices": [],
    "summary": {
      "interventionCount": 6,
      "productCount": 2,
      "deviceCount": 0
    }
  },
  "rawResponse": {
    "interventions": [
      {
        "name": "Faricimab (RO6867461)",
        "role": "Investigational Product",
        "description": "Bispecific antibody targeting Ang-2 and VEGF for the treatment of macular edema secondary to BRVO."
      },
      {
        "name": "Aflibercept",
        "role": "Comparator",
        "description": "Active comparator (anti-VEGF monotherapy) for Part 1 of the study."
      },
      {
        "name": "Sham procedure",
        "role": "Placebo",
        "description": "Procedure mimicking an IVT injection using the blunt end of an empty syringe to maintain masking during Part 2."
      },
      {
        "name": "Systemic corticosteroids",
        "role": "Concomitant Medication",
        "description": "Prohibited within 1 month of screening and during the study."
      },
      {
        "name": "Anti-VEGF IVT",
        "role": "Concomitant Medication",
        "description": "Prior treatment for macular edema due to RVO is a reason for exclusion (washout/prior medication)."
      },
      {
        "name": "Prophylactic antibiotic therapy",
        "role": "Concomitant Medication",
        "description": "Permitted if approved by the Medical Monitor."
      }
    ],
    "products": [
      {
        "name": "Faricimab",
        "doseForm": "Injection",
        "strength": "6 mg",
        "manufacturer": "F. Hoffmann-La Roche Ltd"
      },
      {
        "name": "Aflibercept",
        "doseForm": "Injection",
        "strength": "2 mg",
        "manufacturer": "Not specified"
      }
    ],
    "substances": [
      {
        "name": "Faricimab",
        "description": "Bispecific antibody (RO6867461)"
      },
      {
        "name": "Aflibercept",
        "description": "VEGF trap protein"
      }
    ],
    "administrations": [
      {
        "name": "Faricimab Part 1",
        "dose": "6 mg",
        "frequency": "every 4 weeks",
        "route": "Intravitreal",
        "duration": "Day 1 through Week 20 (6 injections)"
      },
      {
        "name": "Aflibercept Part 1",
        "dose": "2 mg",
        "frequency": "every 4 weeks",
        "route": "Intravitreal",
        "duration": "Day 1 through Week 20 (6 injections)"
      },
      {
        "name": "Faricimab Part 2 (PTI)",
        "dose": "6 mg",
        "frequency": "every 4 weeks to every 16 weeks",
        "route": "Intravitreal",
        "duration": "Week 24 through Week 68"
      }
    ],
    "devices": []
  }
}